NPPB and COVID-19: The observed elevation in biomarker levels of myocardial injury (troponin T) [40], cell death (LDH) [41], myocardial stretch (NT-proBNP) [3] and inflammation (IL-6, CRP, PCT) [42–44], as well as markers of coagulopathy (fibrinogen, vWF) [45, 46] or haematological disorders (leukocytes, platelets, haemoglobin) are all well-described parameters in critically ill patients, as well as in COVID-19 [47].